GI Dynamics Announces Final Data from the ENDO Trial, a Multicenter Study Demonstrating the Potential Use of EndoBarrier to Treat Type II Diabetes and Obesity.
Initial results show the duodenal jejunal bypass liner (DJBL) technology met overall glycemic control efficacy and SAE related device removal safety endpoints
Findings Presented at DDW 2022
BOSTON – June 15, 2022 – GI Dynamics, a medical device company that is developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, announced results from a multicenter study evaluating GI Dynamic’s EndoBarrier® System intended for patients who do not have adequate control of their type 2 diabetes and obesity through their current medication and lifestyle. The data was presented at the annual Digestive Disease Week (DDW) conference in May.
Results from a Multicenter Randomized Sham-controlled Trial of a Duodenal Jejunal Bypass Liner for the Treatment of Type 2 Diabetes Mellitus were presented by Christopher C. Thompson, M.D., Professor at Harvard Medical School and Director of Endoscopy at Brigham and Women’s Hospital.
The study enrolled patients from 2013-2015 and included subjects randomized to DJBL and to a sham procedure with moderate-intensity lifestyle intervention. Primary endpoints included safety, defined as an incidence of serious adverse event (SAE)-related early device removal of ≤15%, and efficacy of glycemic control demonstrated by mean change in HbA1c at 12 months with a superiority margin of ≥0.4% HbA1c over sham.
Analysis revealed that the EndoBarrier System met overall glycemic control efficacy and SAE related device removal safety endpoints, while also providing clinically significant weight loss, and comorbidity improvement.
“Insulin therapy is associated with poor long-term outcomes in patients with type 2 diabetes mellitus and obesity, and bariatric surgery is effective for glycemic control but is higher risk than medical therapy. EndoBarrier is a less invasive intermediate alternative for this struggling population,” said Dr. Thompson. “This novel approach is promising and has the potential to offer patients and clinicians another safe and effective treatment option.”
GI Dynamics stopped the ENDO Trial in 2015, prior to completing enrollment due to a higher than anticipated incidence of liver abscesses. In 2019, the company launched a new US IDE study, the STEP-1 Study, in the United States to study the EndoBarrier System. EndoBarrier is intended for patients who do not have adequate control of their type 2 diabetes and obesity through their current medication and lifestyle. The STEP-1 Trial is currently enrolling patients at 5 clinical study sites across the US.
About GI Dynamics
GI Dynamics Inc. is the developer of the EndoBarrier® System, an endoscopically delivered device therapy that offers a non-surgical, alternative treatment for the treatment of type 2 diabetes and obesity. EndoBarrier® is not approved for sale in the United States and is limited by federal law to investigational use only.
Founded in 2003, GI Dynamics is headquartered in Boston, Massachusetts. For more information, please visit gidynamics.com.
-
Most popular related searches
Related products
Related news
-
Alfa Chemistry Offers Varieties of Marine Biomaterials for Use in Biomedicine, Cosmetics and Nutraceuticals
The US-located chemical supplier Alfa Chemistry has recently unveiled its wide range of marine biomaterials, opening new possibilities in the fields of biomedicine, cosmetics, and nutraceuticals. With an extensive collection of marine polysaccharides, oligosaccharides, bioactive peptides, marine oils, and microalgae powders, researchers and industries alike can explore the potential of marine resources for various applications. Marine biomaterials have gained significant attention due to their diverse bioactive...
-
Analysis of the cryolipolysis slimming machine advantages and disadvantages
Cryolipolysis is a medical aesthetic technique that uses freezing to break down excess fat in the body to achieve a slimming effect. This technique has a great popularity and many people feel confident and beautiful because of the success of this technique to lose weight. As we all know, the medical aesthetic industry has always been a hot industry and cryolipolysis beauty machine as a technique in the medical aesthetic industry, is also very popular in the current medical aesthetic field. Bvlaser is the best...
-
Why Knowledge Is Power In The Treatment Of Obesity
Dr. Ali Tinazli is the CEO of lifespin.health and has 15+ years in Fortune 100 corporate strategy and entrepreneurship (SONY, HP). Obesity rates continue to climb alongside a $254.9 billion global weight loss products and services market. Supplements, smartphone weight loss apps, diet plans and exercise programs are widely available to consumers, yet the World Obesity Federation projects that 1 billion people globally will be obese by 2030. In the U.S., nearly $480 billion in direct healthcare costs annually...
-
Creative Proteomics Metabolomics Expands Service Offering with the Launch of Gut Microbiota Metabolomics Solution
Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS-based metabolomics services for biomedical research institutions as well as biotechnological and pharmaceutical companies. Creative Proteomics Metabolomics announced the launch of the Gut Microbiota Metabolomics Service, aiming to detect the dynamic changes in enterobacterial metabolites and clearly demonstrate the metabolic status of gut flora within the host. This service intuitively studies the relationship between...
-
Inversago Pharma to Participate at the 2023 SVB Securities Global BioPharma Conference
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that François Ravenelle, Ph.D., Chief Executive Officer, and Glenn Vraniak, MBA, Chief Financial Officer, will host investor meetings during the Private Company Exhibition at the 2023 SVB Securities Global Biopharma Conference being held January 31 through February 2, 2023. For additional information or to request a meeting with management,...
Customer comments
No comments were found for GI Dynamics Announces Final Data from the ENDO Trial, a Multicenter Study Demonstrating the Potential Use of EndoBarrier to Treat Type II Diabetes and Obesity.. Be the first to comment!